Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Clinical trial imaging

Harnessing the power of Imaging Phenomics

We’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

iBiopsy

We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Investors

Fredrik Brag at 3 Min Eco

Watch the latest interview with Fredrik Brag, Median’s CEO, for Boursorama 3 Min Eco show. This interview provides an update on the company’s outlook for 2020. It is in French but it has subtitles in English, so no reason to miss it!


Watch

Latest press releases

1 July 2020

Median Technologies to host a live webcast and provide a company update on July 9th, 2020

Median Technologies announced today that Fredrik Brag, CEO of Median Technologies, will provide a company update on July 9th, 2020 at 11:00 am CEST during a webcast.

25 June 2020

Median Technologies appoints Oern Stuge MD, MBA, to its Board of Directors

Median Technologies appoints Oern Stuge MD, MBA, to its Board of Directors. Oern Stuge brings to Median his tremendous expertise in the life sciences industry as well as his unique vision and experience in enterprise development including Go to Market strategy and Medtech  company growth.

17 June 2020

iBiopsy®: promising results on a preliminary study to evaluate the risk of tumor recurrence in patients with primary liver cancer

Median Technologies announces today the results of a preliminary retrospective study on the evaluation of the risk of recurrence for patients with primary liver cancer (HCC – hepatocellular carcinoma) based on a non-invasive biomarker.

4 May 2020

Liquidity Contract Transfer to Louis Capital Markets

Median Technologies is announcing that on March 30, 2020, it concluded a new liquidity contract with the Company Louis Capital Markets in accordance with the Amafi charter. The contract will take effect on the morning of May 4, 2020.

28 April 2020

Median records its best quarterly performance and joins forces with biopharmaceutical companies in the fight against Covid-19

Median Technologies (ALMDT), The Imaging Phenomics Company®, provides an update on its performance for Q1 2020 and a review of its commitment to tackle Covid-19. Revenue of €2.8m, +47% compared with the first quarter of 2019; Order backlog of €44.4m, +€6.1m compared with December 31, 2019; Median Technologies at the service of biopharmaceutical companies involved in Covid-19 clinical trials.

1/5

Median OEGM webcast

Watch our latest OEGM webcast (June 19, 2020) (in French).

Webinars

APRIL 21, 2020 05:00PM CEST

The Evolution of Response Evaluation Criteria in Cancer Immunotherapy

The response evaluation of cancer immunotherapy requires differentiation from traditional chemotherapy; hence, it needs more precise criteria that are compatible with the observed response patterns and the well-documented mechanism of action of these novel treatments. This 30 minutes presentation + 15 minutes Q&A provides a review of the latest advances of imaging assessment for cancer immunotherapy evaluation in clinical trials.

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Powering the phenomics revolution

We’re changing the game, transforming the landscape. We’re capturing the power of big data, cloud computing and artificial intelligence to create a new world of possibilities for biopharma compannies and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision and predictive medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median